Finlay G J, Atwell G J, Baguley B C
Auckland Cancer Society Research Centre, University of Auckland School of Medicine, New Zealand.
Oncol Res. 1999;11(6):249-54.
The action of the anticancer drug amsacrine appears to involve molecular interactions with both DNA and topoisomerase II. It has been shown previously that DNA intercalators can inhibit the action of amsacrine and several other topoisomerase II poisons, presumably as a result of interference with the DNA binding sites for the enzyme. We show here that drug molecules such as N-phenylmethanesulfonamide, which mimic the anilino side chain of amsacrine, inhibit the cytotoxicity against cultured Lewis lung murine carcinoma of amsacrine, amsacrine analogues including asulacrine and DACA (N-[2-(dimethylamino)-ethyl]acridine-4-carboxamide dihydrochloride), and etoposide. In contrast, the cytotoxicity of doxorubicin was slightly increased by co-incubation with N-phenylmethanesulfonamide. The cytotoxicity of amsacrine was also modulated in human Jurkat leukemia, HCT-8 colon, and HT-29 colon cell lines. Because o-AMSA, an amsacrine analogue containing a methoxy group in the ortho rather than in the meta position, is known to be inactive as an antitumor drug, the abilities of the ortho and meta methoxy-substituted derivatives of methyl-N-phenylcarbamate to reverse the cytotoxicity of amsacrine, asulacrine, and DACA were compared. The ortho substitution decreased activity while meta substitution slightly increased it, suggesting that the side chains were binding to a similar site to that occupied by amsacrine. To determine whether the side chain variants actively inhibited the formation of DNA-topoisomerase II covalent complexes, cultured cells were treated with amsacrine or asulacrine, harvested, and lysed directly on acrylamide gels before electrophoresis and Western blotting to identify non-DNA-bound topoisomerase II. Extractable topoisomerase II was depleted in cells incubated with amsacrine but partially restored by coculture with methyl-N-phenylcarbamate. The findings are consistent with the hypothesis that low molecular weight molecules can modulate the effects of topoisomerase II poisons by directly interacting with the enzyme.
抗癌药物安吖啶的作用似乎涉及与DNA和拓扑异构酶II的分子相互作用。先前已经表明,DNA嵌入剂可以抑制安吖啶和其他几种拓扑异构酶II毒物的作用,推测这是由于干扰了酶的DNA结合位点。我们在此表明,诸如N-苯基甲磺酰胺之类的药物分子,其模拟安吖啶的苯胺基侧链,可抑制安吖啶、包括阿舒拉嗪和DACA(N-[2-(二甲氨基)-乙基]吖啶-4-甲酰胺二盐酸盐)的安吖啶类似物以及依托泊苷对培养的Lewis肺癌小鼠癌细胞的细胞毒性。相反,与N-苯基甲磺酰胺共同孵育会使阿霉素的细胞毒性略有增加。安吖啶的细胞毒性在人Jurkat白血病、HCT-8结肠和HT-29结肠癌细胞系中也受到调节。由于o-AMSA(一种在邻位而非间位含有甲氧基的安吖啶类似物)已知作为抗肿瘤药物无活性,因此比较了甲基-N-苯基氨基甲酸酯的邻位和间位甲氧基取代衍生物逆转安吖啶、阿舒拉嗪和DACA细胞毒性的能力。邻位取代降低活性,而间位取代则使其略有增加,这表明侧链与安吖啶占据的类似位点结合。为了确定侧链变体是否积极抑制DNA-拓扑异构酶II共价复合物的形成,将培养的细胞用安吖啶或阿舒拉嗪处理,收获后直接在丙烯酰胺凝胶上裂解,然后进行电泳和蛋白质印迹以鉴定非DNA结合的拓扑异构酶II。在用安吖啶孵育的细胞中,可提取的拓扑异构酶II减少,但与甲基-N-苯基氨基甲酸酯共培养可部分恢复。这些发现与低分子量分子可通过与酶直接相互作用来调节拓扑异构酶II毒物作用的假设一致。